Nephrolytics
Transforming Kidney Care Through AI-Driven Clinical Intelligence

Dr. Fahim Rahim, MD, MBA, Nephrologist, Founder and CEO, Nephrolytics

Nephrolytics is a category-defining platform called Saya™ — the first-of-its-kind AiPOC: Agentic Infrastructure at Point of Care.

While others build piecemeal features around static EMRs, Saya™ is purpose-built to transform how care is delivered at the moment it matters most. Point of care is where over 90 percent of medical decisions are made, but it’s also where clinicians face the greatest burden from fragmented systems, documentation overload, and lack of real-time insights.

Saya™ acts as an intelligent operating layer on top of the EMR, delivering actionable, domain-specific support that enhances clinical judgment, streamlines workflows, and improves efficiency and outcomes. This isn’t just automation—its augmentation, and it represents a fundamental rethinking of the EMR paradigm.

Built by practicing nephrologists, Nephrolytics’ flagship platform, Saya™, is tailored to the real-world demands of kidney disease management. Purpose-built for the specialty, Saya™ automates three of the most time-consuming clinical tasks, including data aggregation, integration, and documentation, which can consume up to 75 percent of a clinician’s time. By streamlining these processes, Saya™ enables clinicians to focus more on patient care, reducing administrative burden and helping prevent burnout.

The need for such a solution is particularly urgent in nephrology, where clinician shortages are growing. Nearly 40 percent of nephrology fellowship positions go unfilled, even as the number of patients with chronic kidney disease continues to climb. Nephrolytics focuses on this field not only due to its domain expertise but because of nephrology’s inherently complex and data-intensive nature. Saya™ helps bridge the gap between rising care demands and a shrinking workforce.

“While others offer piecemeal tools like scribes or analytics, we are the only full-stack AI or agentic solution dedicated to kidney disease care, built specifically for the nephrology workflow,” says Dr. Fahim Rahim, MD, MBA, nephrologist, founder and CEO of Nephrolytics.

Saya™’s Smart Summary feature aggregates and synthesizes EMR data, surfacing relevant patient insights without the need to manually sift through fragmented records. Complementing this, the Smart Checklist and Recommendations feature uses predictive analytics to identify care gaps and suggest next steps, enabling nephrologists to focus on high-impact clinical decisions.

To drive clinical relevance further, Nephrolytics is developing proprietary Retrieval-Augmented Generation (RAG) models trained on kidney-specific datasets and built atop open-source large language models. These models power real-time insights that help identify and resolve care gaps, while also optimizing clinical and financial outcomes.

From Clinical Results to Scalable Growth

Although Nephrolytics is currently focused on nephrology, the platform is designed for scalability. Its intelligent workflow capabilities can be adapted to other data-intensive specialties such as primary care and pediatrics, bringing broader value to healthcare systems.

One real-world example demonstrates Saya™’s impact, wherein a nephrologist was able to diagnose and initiate a care plan for a rare genetic condition, HLRCC, during a patient’s first visit, fueled by Saya™’s ability to interpret complex genomic data in real time. What would have typically required follow-up research and an additional appointment was handled on the spot, saving time, easing patient anxiety, and improving outcomes.

Early adopters report significant time savings, improved documentation, and less after-hours “pajama time.” Some clinicians even say they now prefer using Saya™ over traditional EMRs due to its intuitive design and immediate, context-rich support.

After successfully delivering Phase One, encompassing intelligent data aggregation, contextual recommendations, and AI-driven documentation, Nephrolytics is now preparing for its bridge round to accelerate growth. Next on the roadmap is Conversational AI, enabling clinicians to interact with Saya™ in real time by asking patient-specific questions, receiving evidence-based recommendations, and making informed decisions—all within the clinical workflow.

The platform is also expanding into risk prediction analytics, helping care teams identify and prioritize high-risk patients. These capabilities will support better resource allocation, improve care quality, and reinforce revenue integrity across high-volume specialties.

Treading ahead, Nephrolytics envisions an AI-powered future that extends beyond the clinical team to empower patients directly. The company is exploring tools that can transform clinical data into clear, actionable insights for patients, enhancing understanding, adherence, and engagement across the continuum of care.